Last reviewed · How we verify
Naloxone, intranasal
Naloxone reverses opioid overdose by competitively binding to opioid receptors.
Naloxone reverses opioid overdose by competitively binding to opioid receptors. Used for Reversal of opioid overdose.
At a glance
| Generic name | Naloxone, intranasal |
|---|---|
| Sponsor | Norwegian University of Science and Technology |
| Drug class | opioid antagonist |
| Target | opioid receptors |
| Modality | Small molecule |
| Therapeutic area | Emergency Medicine |
| Phase | Phase 3 |
Mechanism of action
Naloxone works by rapidly displacing opioids from their receptors in the brain and spinal cord, restoring normal breathing and circulation. This is achieved through competitive inhibition, where naloxone binds to the same receptors as opioids, preventing them from exerting their effects. As a result, naloxone can quickly reverse the life-threatening symptoms of opioid overdose.
Approved indications
- Reversal of opioid overdose
Common side effects
- Nausea
- Vomiting
- Headache
- Dizziness
- Anxiety
Key clinical trials
- Neural Mechanisms of Immersive Virtual Reality in Chronic Pain (PHASE1, PHASE2)
- Patient and Caregiver Attitudes and Beliefs Regarding Prescription of Intranasal Naloxone Spray for Opioid Overdose
- Novel Approach for the Prevention of Hypoglycemia Associated Autonomic Failure (HAAF) (PHASE4)
- Pharmacokinetics of Intravenous and Intranasal Formulations of Naloxone in Healthy Volunteers. (PHASE1)
- Pharmacodynamic Evaluation of Intranasal Nalmefene (PHASE1)
- Pharmacodynamic Evaluation of Intramuscular Nalmefene Autoinjector 1.5 mg Compared to Intranasal Narcan 4 mg (PHASE1)
- Neural Correlates of Hypoalgesia Driven by Observation (PHASE2)
- Naltrexone for Overdose Prevention (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Naloxone, intranasal CI brief — competitive landscape report
- Naloxone, intranasal updates RSS · CI watch RSS
- Norwegian University of Science and Technology portfolio CI